Patients in the U.S. have been given digital cancer drugs for the first time in a bid to improve outcomes and adherence.
The pill combines the drug capecitabine, used for grade 3 and 4 colorectal cancer with a new age ingestible sensor developed by Proteus itself.
Proteus was the mastermind behind the first ever ‘digital pill’ approved by the FDA. The original drug was Abilify MyCite, a form of Otsuka pharmaceuticals’ mental health drug ‘Abilify’ that then included a sensor to track ingestion of the drug using a smartphone.
The ingestible sensor essentially aims to optimise treatment regimens, while upholding the patient’s privacy it captures, records and shares information about the dose, time and type of oral chemotherapy taken.
This information, alongside resting heart rate, can then be shared with the patient’s consent to the pharmacist, physician or carer.
Andrew Thompson, CEO and Co-founder of Proteus Digital Health, said: “Currently, providers make decisions about oral chemotherapy based on patients’ best knowledge of their medication taking.
For the first time, digital oncology medicines give providers and caregivers new insights and ability to engage with more specific information in the remote care of colorectal cancer patients.
Based on our data around the use of digital medicines in other treatment areas, we believe this will enable oncology patients to stay on their therapy longer, avoid hospital admissions, and have better responses to therapy overall.”